Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTRB1 | P17538 | 2/20 | 0.59 |
| ▸ | CTSB | P07858 | 6/20 | 0.54 |
| ▸ | CTSL | P07711 | 5/20 | 0.54 |
| ▸ | TACR1 | P25103 | 2/20 | 0.53 |
| ▸ | CTSS | P25774 | 3/20 | 0.53 |
| ▸ | CTSK | P43235 | 1/20 | 0.52 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10508932 | 1.00 | CTRB1 (0.59) | CTRB1CTSBCTSLTACR1CTSS | |
| SCHEMBL6220038 | 1.00 | CTRB1 (0.59) | CTRB1CTSBCTSLTACR1CTSS | |
| SCHEMBL7797822 | 0.92 | CTSL (0.53) | CTRB1CTSBCTSLCTSSCTSK | |
| SCHEMBL7789548 | 0.90 | ATM (0.60) | CTRB1CTSBCTSLCTSSCTSK | |
| SCHEMBL5857579 | 0.88 | CTRB1 (0.48) | CTRB1CTSBCTSLTACR1CTSS | |
| SCHEMBL5929819 | 0.88 | CTRB1 (0.48) | CTRB1CTSBCTSLTACR1CTSS | |
| SCHEMBL9741528 | 0.88 | CTRB1 (0.59) | CTRB1CTSBCTSLTACR1CTSS | |
| SCHEMBL7310419 | 0.88 | CTSL (0.62) | CTRB1CTSBCTSLTACR1CTSS | |
| SCHEMBL2736209 | 0.88 | CTSL (0.62) | CTRB1CTSBCTSLTACR1CTSS | |
| SCHEMBL2736217 | 0.88 | CTSL (0.62) | CTRB1CTSBCTSLTACR1CTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040266871-A1 | Methods for treating alzheimer's disease using quinaldoyl-amine derivatives of oxo-and hydroxy-substituted hydrocarbons | PHARMACIA & UPJOHN | 2004-12-30 | — | — | US | disclosed |
| EP-0633881-B1 | AMINE DERIVATIVES OF OXO- AND HYDROXY-SUBSTITUED HYDROCARBONS | NARHEX LTD (HK) | 2003-10-29 | — | — | EP | disclosed |
| EP-0748801-B1 | 2-ISOXAZOLINE DERIVATIVE AND PROCESS FOR PRODUCING THE SAME, AND PROCESS FOR PRODUCING RELATED DERIVATIVES FROM THE SAME | DAICEL CHEM (JP) | 2001-12-19 | — | — | EP | disclosed |
| US-6258806-B1 | PEPTIDES WITH CYCLIC DIAZAALKANES FOR PREVENTION OF PREMATURE METABOLISM METHOD FOR INHIBITING AN HIV PROTEASE IN A MAMMAL IN NEED OF SUCH PROTEASE INHIBITION, COMPRISING ADMINISTERING TO SAID MAMMAL AN EFFECTIVE DOSAGE | NARHEX LIMITED (HK) | 2001-07-10 | — | — | US | disclosed |
| US-6018069-A | 2-isoxazoline derivative and process for producing the same and process for producing related derivatives from the same | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2000-01-25 | — | — | US | disclosed |
| US-5994558-A | 2-isoxazoline derivative and process for producing the same; and process for producing related derivatives from the same | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1999-11-30 | — | — | US | disclosed |
| US-5990135-A | FOR TREATING A RETROVIRAL INFECTION SUCH AS HIV INFECTION; FOR EXAMPLE 5S-N-((2-PYRIDINYL)METHOXYCARBONYL)VALINYLAMINO-2-((N-3 -PYRIDINYL)METHOXYCARBONYL)AMINO-4S-HYDROXY-1,6-DIPHENYL-2-AZAHEXANE AND OTHER COMPOUNDS OF GIVEN FORMULA | ABBOTT LABORATORIES (US) | 1999-11-23 | — | — | US | disclosed |
| US-5962692-A | 2-isoxazoline derivative and process for producing the same, and process for producing related derivatives from the same | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1999-10-05 | — | — | US | disclosed |
| US-5942504-A | INHIBITORS OF RETROVIRAL PROTEASES; TREATMENT OF AIDS AND HIV | NARHEX LIMITED (HK) | 1999-08-24 | — | — | US | disclosed |
| US-5750717-A | 2-isoxazoline derivative and process for producing the same, and process for producing related derivatives from the same | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1998-05-12 | — | — | US | disclosed |
| US-5679688-A | RETROVIRAL PROTEASE INHIBITORS; AIDS THERAPY | NARHEX LIMITED (HK) | 1997-10-21 | — | — | US | disclosed |
| US-5631376-A | PEPTIDE DERIVATIVES FOR TREATMENT OF AIDS | ABBOTT LABORATORIES (US) | 1997-05-20 | — | — | US | disclosed |
| US-5621109-A | OXAZOLE/THIAZOLE DERIVATIVES OF HYDROXYMETHYL HYDRAZONES; SIDE EFFECT REDUCTION | ABBOTT LABORATORIES (US) | 1997-04-15 | — | — | US | disclosed |
| EP-0748801-A1 | 2-ISOXAZOLINE DERIVATIVE AND PROCESS FOR PRODUCING THE SAME, AND PROCESS FOR PRODUCING RELATED DERIVATIVES FROM THE SAME | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1996-12-18 | — | — | EP | disclosed |
| EP-0683772-A1 | RETROVIRAL PROTEASE INHIBITING COMPOUNDS | ABBOTT LABORATORIES (US) | 1995-11-29 | — | — | EP | disclosed |
| US-5461067-A | For HIV infections | ABBOTT LABORATORIES (US) | 1995-10-24 | — | — | US | disclosed |
| EP-0683772-A4 | RETROVIRAL PROTEASE INHIBITING COMPOUNDS. | ABBOTT LAB (US) | 1995-09-27 | — | — | EP | disclosed |
| WO-1994019332-A1 | RETROVIRAL PROTEASE INHIBITING COMPOUNDS | ABBOTT LABORATORIES (US) | 1994-09-01 | — | — | WO | disclosed |
| WO-1993018006-A1 | AMINE DERIVATIVES OF OXO- AND HYDROXY-SUBSTITUED HYDROCARBONS | NARHEX LIMITED (HK) | 1993-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266871-A1 | Methods for treating alzheimer's disease using quinaldoyl-amine derivatives of oxo-and hydroxy-substituted hydrocarbons | BACE1, BACE2, PSEN1 | CTRB1 445/4885CTSB 67/4885CTSL 456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.